Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.41 |
| ▸ | HTR2C | P28335 | 7/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24018791 | 0.87 | SCN9A (0.39) | HTR2AHTR2CSCN9ASCN5ARIPK1 | |
| SCHEMBL22957828 | 0.86 | SCN9A (0.39) | HTR2AHTR2CSCN9ASCN5ARIPK1 | |
| SCHEMBL24018827 | 0.86 | SCN9A (0.38) | HTR2AHTR2CSCN9ASCN5ARIPK1 | |
| SCHEMBL22957663 | 0.82 | AXL (0.43) | HTR2AHTR2CSLC6A4RIPK1 | |
| SCHEMBL20472323 | 0.81 | HTR2A (0.41) | HTR2AHTR2CSCN9AHTR2B | |
| SCHEMBL29786587 | 0.81 | HTR2A (0.41) | HTR2AHTR2CSCN9AHTR2B | |
| SCHEMBL22389492 | 0.80 | RIPK1 (0.44) | HTR2AHTR2CSCN9ASCN5ARIPK1 | |
| SCHEMBL28331550 | 0.79 | SCN9A (0.42) | HTR2AHTR2CSCN9ASCN5AHTR2B | |
| SCHEMBL22957659 | 0.79 | HTR2A (0.43) | HTR2AHTR2CSLC6A4RIPK1HTR2B | |
| SCHEMBL22957830 | 0.79 | AXL (0.46) | HTR2AHTR2CSLC6A4RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3580220-B1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-17 | — | — | EP | disclosed |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | HTR2A 2314/4885HTR2C 3116/4885SLC6A4 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.